A Phase 3 interventional study of Donepezil in Dementia, Vascular and Dementia, Mixed, sponsored by Pfizer. Terminated at 30 sites in Canada. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2015-03-24.
Sponsored by Pfizer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
To document effectiveness, safety, and tolerability of donepezil in patients with mixed AD/VaD, and to further document the effectiveness, safety, and tolerability of donepezil in patients with VaD. The effects of donepezil on executive functioning, behavior, general cognition, ADLs and global functioning will be assessed.
The trial was terminated on October 15, 2007 due to difficulties in recruiting the subjects. There were no safety or efficacy concerns regarding the study medication in the decision to terminate the trial.
183 studies on the registry are indexed under Dementia, Vascular; 42 are open to participants now.
This study's enrollment of 149 is above the median of 123 across 116 interventional studies indexed under Dementia, Vascular.
Browse Dementia, Vascular studies →Pfizer is the lead sponsor of 3,337 studies on the registry; 146 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Donepezil
donepezil 5mg/day for 6 weeks and then 5 to 10mg/day for 18 weeks
Change in Total Score of Standardized Mini-Mental State Examination (sMMSE); Full Analysis Set
Change from baseline in sMMSE total score. Change: mean total score at observation minus mean total score at baseline. Total score is derived by adding all subscores and ranges from 0 to 30; a higher score indicates a better cognitive state.
Time frame: Baseline, week 12, week 24
Disability Assessment for Dementia Change From Baseline; Activities of Daily Living (ADL) Domain.
The ADL domain includes 17 yes/no questions on four items (hygiene, dressing, continence, eating). Score equals number of questions answered yes multiplied by 100 divided by number of questions answered. Change: Mean ADL score at observation minus mean ADL score at baseline.
Time frame: Baseline, week 12, week 24
Disability Assessment for Dementia Change From Baseline; Instrumental ADL (IADL) Domain.
IADL domain consists of 23 yes-no questions on 6 items (meal preparation, telephoning, going out, finance \& correspondence, medications, leisure \& housework. Change: Mean IADL score at observation minus mean IADL score at baseline. Total IADL score = number of questions answered yes multiplied by 100 divided by total number of questions answered
Time frame: Baseline, 12 weeks, 24 weeks
Disability Assessment for Dementia (DAD) Change From Baseline Total Score; Full Analysis Set (FAS)
DAD total score equals total number of questions answered yes multiplied by 100 divided by total number of questions answered.
Time frame: Baseline, week 12, week 24
Free-hand Drawing Test (CLOX 1) Change From Baseline; Full Analysis Set (FAS)
The ability to draw a clock free-hand. Scored on a scale from 1 to 15; lower scores indicate higher impairment. Change: Mean CLOX 1 score at observation minus mean CLOX score at baseline.
Time frame: Baseline, 12 weeks, 24 weeks
Copied Clock Drawing Test (CLOX 2) Change From Baseline; Full Analysis Set (FAS)
The ability to copy a drawing of a clock. Scored on a scale from 1 to 15; lower scores indicate higher impairment. Change: Mean CLOX 2 score at observation minus mean CLOX 2 score at baseline.
Time frame: Baseline, 12 weeks, 24 weeks
CLOX Differential Score Change From Baseline; Full Analysis Set (FAS)
CLOX differential score equals the difference between the score for CLOX 2 and the score for CLOX 1, values range from 15 to 0, with 0 indicating perfect executive function, and a worsening with the increasing score.
Time frame: Baseline, 12 weeks, 24 weeks
Phonectic Fluency Total Score From Baseline; Full Analysis Set (FAS)
The number of words a particpant can generate in 1 minute.
Time frame: Baseline, 12 weeks, week 24
Neuropsychiatric Inventory Questionnaire (NPI-Q) Score Change From Baseline; Full Analysis Set (FAS)
NPI-Q measures severity of behavioural manifestations of dementia \& the level of distress each symptom gives the main caregiver, 1 (mild), 3 (severe), 0 if symptom absent, NPI-Q also measures the caregiver distress associated with each symptom,0(no distress)to 5(very severe), total score equals sum of individual item scores \& ranges from 0 to 36
Time frame: Baseline, 12 weeks, 24 weeks
Neuropsychiatric Inventory Questionnaire Distress (NPI-Q-D) Score Change From Baseline; Full Analysis Set (FAS)
The total NPI-Q-D score is equal to the sum of all indiviudal symptom distress scale scores with a range of 0 to 60
Time frame: Baseline, week 12, week 24
Clinical Global Impressions Severity Score (CGI-S) Clinical Global Impressions Severity Score Improvement(CGI-I)Change From Baseline, Full Analysis Set (FAS)
Scale measures subject's clinical condition at baseline for severity (CGI-S) \& for improvement from baseline (CGI-I). At baseline subject rated on numerical scale, 1 (not at all ill) to 7 (most extremely ill). At follow up subject rated on 7 point Likert scale from 1(very much improved) to 7(very much worse) \& 4 indicates no change from baseline
Time frame: Baseline, week 24
Clinical Global Impressions Severity (CGI-S)
Scale measures subject's clinical condition at baseline for severity (CGI-S) subject rated on numerical scale, 1 (not at all ill) to 7 (most extremely ill).
Time frame: Baseline
Clinical Global Impressions Improvement (CGI-I)
Scale measures subject's clinical condition for improvement from baseline (CGI-I)subject rated on 7 point Likert scale from 1(very much improved) to 7(very much worse) \& 4 indicates no change from baseline
Time frame: Week (wk) 24
Clinical Global Impressions Improvement (CGI-I) Dichotomized Response
Scale measures subject's (CGI-I) rated on categorial 7 point Likert scale 1 (very much improved) to 7 (very much worse) with 4 indicating no change from baseline. A dichotomized variable was created: responder = CGI-I score of 4 or less; non-responder = CGI-I score of 5 or more
Time frame: Baseline, week 24
Study was conducted in Canada in 30 centres.
| Milestone | Donepezil |
|---|---|
| Started | 149 |
| Completed | 116 |
| Not completed | 33 |
| Withdrew: Death | 2 |
| Withdrew: Adverse event | 19 |
| Withdrew: Withdrawal by subject | 6 |
| Withdrew: Protocol violation | 3 |
| Withdrew: Arrived early for last visit in error | 1 |
| Withdrew: Subject felt pill not effective enough | 1 |
| Withdrew: Lost to follow-up | 1 |
Change from baseline in sMMSE total score. Change: mean total score at observation minus mean total score at baseline. Total score is derived by adding all subscores and ranges from 0 to 30; a higher score indicates a better cognitive state.
| Score on a scale | Donepezil |
|---|---|
| Week 12 (n=124) | 0.41 ± 3.10 |
| Week 24 (n=114) | 0.69 ± 3.2 |
| Week 24 LOCF (n=137) | 0.48 ± 3.25 |
The ADL domain includes 17 yes/no questions on four items (hygiene, dressing, continence, eating). Score equals number of questions answered yes multiplied by 100 divided by number of questions answered. Change: Mean ADL score at observation minus mean ADL score at baseline.
| score on a scale | Donepezil |
|---|---|
| week 12 (n=124) | 1.68 ± 13.23 |
| week 24 (n=114) | -1.61 ± 19.68 |
| week 24 LOCF (n=137) | -1.88 ± 18.15 |
IADL domain consists of 23 yes-no questions on 6 items (meal preparation, telephoning, going out, finance \& correspondence, medications, leisure \& housework. Change: Mean IADL score at observation minus mean IADL score at baseline. Total IADL score = number of questions answered yes multiplied by 100 divided by total number of questions answered
| score on a scale | Donepezil |
|---|---|
| week 12 (n=124) | 1.68 ± 18.01 |
| week 24 (n=114) | 0.20 ± 22.37 |
| week 24 LOCF (n=137) | 1.31 ± 22.30 |
DAD total score equals total number of questions answered yes multiplied by 100 divided by total number of questions answered.
| score on a scale | Donepezil |
|---|---|
| week 12 (n=124) | 1.71 ± 13.18 |
| week 24 (n=114) | -0.12 ± 18.01 |
| week 24 LOCF (n=137) | 0.17 ± 17.01 |
The ability to draw a clock free-hand. Scored on a scale from 1 to 15; lower scores indicate higher impairment. Change: Mean CLOX 1 score at observation minus mean CLOX score at baseline.
| Score on a scale | Donepezil |
|---|---|
| Week 12 (n=123) | -0.03 ± 3.08 |
| Week 24 (n=111) | 0.95 ± 3.13 |
| Week LOCF (n=137) | 0.74 ± 3.13 |
The ability to copy a drawing of a clock. Scored on a scale from 1 to 15; lower scores indicate higher impairment. Change: Mean CLOX 2 score at observation minus mean CLOX 2 score at baseline.
| Score on scale | Donepezil |
|---|---|
| week 12 (n=117) | 0.28 ± 3.35 |
| week 24 (n=106) | 0.84 ± 2.92 |
| week 24 LOCF (n=131) | 0.51 ± 3.09 |
CLOX differential score equals the difference between the score for CLOX 2 and the score for CLOX 1, values range from 15 to 0, with 0 indicating perfect executive function, and a worsening with the increasing score.
| Score on a scale | Donepezil |
|---|---|
| week 12 (n=117) | 0.26 ± 3.50 |
| week 24 (n=106) | -0.35 ± 3.31 |
| week 24 LOCF (n=131) | -0.44 ± 3.36 |
The number of words a particpant can generate in 1 minute.
| score on scale | Donepezil |
|---|---|
| week 12 (n=123) | 0.84 ± 2.85 |
| week 24 (n=113) | 0.92 ± 3.38 |
| week 24 LOCF (n=136) | 0.83 ± 3.29 |
NPI-Q measures severity of behavioural manifestations of dementia \& the level of distress each symptom gives the main caregiver, 1 (mild), 3 (severe), 0 if symptom absent, NPI-Q also measures the caregiver distress associated with each symptom,0(no distress)to 5(very severe), total score equals sum of individual item scores \& ranges from 0 to 36
| Score on scale | Donepezil |
|---|---|
| week 12 (n=124) | -1.06 ± 4.02 |
| week 24 (n=114) | -1.20 ± 4.19 |
| week 24 LOCF (n=137) | -1.19 ± 4.03 |
The total NPI-Q-D score is equal to the sum of all indiviudal symptom distress scale scores with a range of 0 to 60
| Score on a scale | Donepezil |
|---|---|
| week 12 (n=124) | -0.95 ± 5.54 |
| week 24 (n=114) | -1.37 ± 6.25 |
| week 24 LOCF (n=137) | -1.08 ± 6.04 |
Scale measures subject's clinical condition at baseline for severity (CGI-S) \& for improvement from baseline (CGI-I). At baseline subject rated on numerical scale, 1 (not at all ill) to 7 (most extremely ill). At follow up subject rated on 7 point Likert scale from 1(very much improved) to 7(very much worse) \& 4 indicates no change from baseline
| Score on a scale | Donepezil |
|---|---|
| Baseline (n=136) | 3.40 ± 0.67 |
| Week 24 (n=116) | 3.32 ± 1.21 |
| Week 24 LOCF (n=136) | 3.40 ± 1.19 |
Scale measures subject's clinical condition at baseline for severity (CGI-S) subject rated on numerical scale, 1 (not at all ill) to 7 (most extremely ill).
| Participants | Donepezil |
|---|---|
| Normal, not at all ill (n=136) | 2 |
| Borderline mentally ill (n=136) | 4 |
| Mildly ill (n=136) | 72 |
| Moderately ill (n=136) | 54 |
| Markedly ill (n=136) | 4 |
| Severely ill (n=136) | 0 |
| Among the most extremely ill patients (n=136) | 0 |
Scale measures subject's clinical condition for improvement from baseline (CGI-I)subject rated on 7 point Likert scale from 1(very much improved) to 7(very much worse) \& 4 indicates no change from baseline
| Participants | Donepezil |
|---|---|
| Wk 24 Very much improved (n=116) | 3 |
| Wk 24 Much improved (n=116) | 27 |
| Wk 24 Minimally improved (n=116) | 44 |
| Wk 24 No change (n=116) | 21 |
| Wk 24 Minimally worse (n=116) | 14 |
| Wk 24 Much worse (n=116) | 7 |
| Wk 24 Very much worse (n=116) | 0 |
| Wk 24 LOCF Very much improved (n=136) | 4 |
| Wk 24 LOCF Much improved (n=136) | 27 |
| Wk 24 LOCF Minimally improved (n=136) | 49 |
| Wk 24 LOCF No change (n=136) | 30 |
| Wk 24 LOCF Minimally worse (n=136) | 19 |
| Wk 24 LOCF Much worse (n=136) | 7 |
| Wk 24 LOCF Very much worse (n=136) | 0 |
Scale measures subject's (CGI-I) rated on categorial 7 point Likert scale 1 (very much improved) to 7 (very much worse) with 4 indicating no change from baseline. A dichotomized variable was created: responder = CGI-I score of 4 or less; non-responder = CGI-I score of 5 or more
| Particpants | Donepezil |
|---|---|
| Week 24 Responder (n=116) | 95 |
| Week 24 Non-responder (n=116) | 21 |
| Week 24 LOCF Responder (n=136) | 110 |
| Week 24 LOCF Non-responder (n=136) | 26 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Donepezil | — | — | — |
| Event | Donepezil |
|---|---|
| Hip fractureInjury, poisoning and procedural complications | 3/148 |
| Myocardial infarctionCardiac disorders | 2/148 |
| Chest painGeneral disorders | 2/148 |
| UrosepsisInfections and infestations | 2/148 |
| Cerebrovascular accidentNervous system disorders | 2/148 |
| Cardiac failure congestiveCardiac disorders | 1/148 |
| Sick sinus syndromeCardiac disorders | 1/148 |
| Abdominal painGastrointestinal disorders | 1/148 |
| Duodenal ulcerGastrointestinal disorders | 1/148 |
| General physical health deteriorationGeneral disorders | 1/148 |
| Event | Donepezil |
|---|---|
| NauseaGastrointestinal disorders | 26/148 |
| DiarrhoeaGastrointestinal disorders | 15/148 |
| InsomniaPsychiatric disorders | 15/148 |
| DizzinessNervous system disorders | 11/148 |
| VomitingGastrointestinal disorders | 9/148 |
| AnorexiaMetabolism and nutrition disorders | 8/148 |
| HeadacheNervous system disorders | 8/148 |
| Age, Customized(Participants) | Donepezil |
|---|---|
| < 45 | 0 |
| 45-64 | 20 |
| >= 65 | 129 |
| Sex: Female, Male(Participants) | Donepezil |
|---|---|
| Female | 82 |
| Male | 67 |
The record gives a start of Jun 2005, a primary completion of Apr 2008 and a completion of Apr 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2009, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Donepezil